Drug Recovery: Effect of Astemizole - Methylene Blue Combination Therapy against *Plasmodium* Strains in vitro

Joyce Nyirongo¹,²*, Lucy Kamau³, Jemimah Simbauni¹, Victor Mwangi²,⁴, Esther Kagasi², Faith Onditi² and Hastings Ozwara²

¹Department of Zoological Sciences, Kenyatta University, Nairobi, Kenya.
²Department of Tropical and Infectious Diseases, Institute of Primate Research, Nairobi, Kenya.
³Department of Animal Sciences, Kenyatta University, Nairobi, Kenya.
⁴Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

**Authors’ contributions**

This work was carried out in collaboration among all authors. Authors VM and FO prepared the concept. Authors JN, EK and FO collected the data. Authors JN and FO analyzed the data. Authors FO and HO supervised experiments. Authors JN, JS, FO and LK prepared the manuscript. All authors read and approved the manuscript.

**Article Information**

Editors:
(1) Dr. Ahmed Tabbabi, Jichi Medical University, Japan.
Reviewers:
(1) Jesús Carlos Ruvalcaba Ledezma, Universidad Autónoma del Estado de Hidalgo, México.
(2) K. Venkata Gopaiah, St. Mary’s Group of Institutions, India.
Complete Peer review History: [http://www.sdiarticle4.com/review-history/60063](http://www.sdiarticle4.com/review-history/60063)

Received 14 June 2020
Accepted 19 August 2020
Published 01 September 2020

**ABSTRACT**

*Plasmodium* species are protozoa from the Apicomplexa phylum which cause malaria. In the tropics and sub-tropics, approximately 3.3 billion people are threatened by this disease. Artemisinin Combination Therapy, has been reported to have a possible emergence of resistance. Therefore, there is an urgent need for new drug formulations. Drug repurposing offers an appealing alternative to *de novo* drug development. Although astemizole and methylene blue have been reported to have anti-malarial properties, their efficacy when used in combination has not been studied. Five concentrations ranging from 7.81 µg/ml to 125 µg/ml were combined in various ratios and assessed against two *Plasmodium* strains *in vitro*. Parasite load (per µl of blood) was determined by

*Corresponding author: E-mail: nyirongojoyce@gmail.com;*
1. INTRODUCTION

Malaria is a parasitic disease caused by protozoa parasites of the genus *Plasmodium*. As of year 2018, 228 million cases of malaria were recorded globally [1]. At present, chemotherapy still remains one of the major approaches for both malaria prevention and remedy [2]. However, in some endemic areas, delayed clearance of the disease in patients to whom antimalarial drugs were administered remains a great concern. An interesting observation is that, the patients still record high levels of parasitemia despite having a considerable amount of anti-malarial drugs in their body systems [3]. Due to the widespread anti-malarial drug resistance, combination therapy has been advocated for by WHO rather than monotherapy which is becoming less effective [4]. The use of combination therapies with artemisinin was aimed at combating parasite resistance against monotherapies that was reported in laboratory settings [5]. *Plasmodium* resistance in addition to chloroquine has had a negative impact on malaria treatment [6]. Furthermore, the emergence of artemisinin resistant *Plasmodium falciparum* strains along the Thai-Cambodia border negatively impacted disease control efforts [7]. The traditional methods of drug development are not only time consuming but also costly. Furthermore, 90% of drug trials fail as early as the developmental stage [3]. Thus drug repurposing provides an alternative and favorable channel in faster development of future antimalarial drug candidates.

Astemizole (AST), with the common trade names Histmanol, Cilergil and Almizol, on the other hand, is an artificial piperidinyl-benzimidazol derivative that has anti-allergic properties [8]. This drug works by competing with histamine at the H₁-receptor sites in the uterus, gastro-intestinal tract and bronchial muscles [9]. Orally administered astemizole is metabolized into O-desmethyastemizole [10]. The O-desmethyastemizole concentration in serum rises higher than that of astemizole is eventually eliminated in 9 -13 days. It has been observed that during the intra-erythrocytic stage, *P. falciparum* crystallizes heme released from the disintegration of hemoglobin within the food vacuole to enhance their survival. Astemizole works by inhibiting this crystallization process thereby suppressing parasite survival [11]. Astemizole inhibits the growth of chloroquine sensitive and resistant *Plasmodium* parasites *in vitro* [12].

The phenothiazinium salt, methylene blue (MB) is a synthesized textile dye. In 1891, it was approved for use as the initial synthetic antimalarial [5]. However, its use was discontinued when chloroquine was introduced into the market because chloroquine served as a better remedy against malaria [13]. Methylene blue inhibits *P. falciparum* glutathione reductase and reverses chloroquine resistance. In the trophozoite stage, *P. falciparum*, metabolizes glutathione at an intense rate to protect against oxidative stress [7]. Glutathione helps in antioxidative protection and in its reduced state, it supports parasite growth by providing electrons for the deoxyribonucleotide (DNA) [7]. It also prevents the polymerization of heme into hemozoin [13]. Methylene blue specifically inhibits glutathione reductase and possibly reverses parasite resistance to chloroquine [13,14]. In a study, 99% chemo suppression of methylene blue was demonstrated against rodent malaria at 45 mg/kg by day 5 post treatment [14].

There is an urgent need to develop new formulations [12]. Drug repurposing offers this.

Keywords: Drug repurposing; malaria; astemizole; methylene blue; *Plasmodium falciparum*. 

microscopy. The results were represented as mean ± standard error. ANOVA analysis was used to determine differences in the treatment groups at *p*<0.05. Antiplasmodial activity was observed in all drugs that were cultured with *P. falciparum* chloroquine sensitive (3D7) and chloroquine resistant (W2) strains. Strain dependent differences were observed in the efficacy scores of the tested drugs. Astemizole-methylene blue combinations of ratios 1:1, 3:1 and 1:3 interacted antagonistically. The least antagonistic interactions were 3:1 and 1:3 ratios at 31.25 µg/ml against the *Plasmodium* strains (FIC of 2.2 and 2.6 respectively). Astemizole antagonized methylene blue in the combinations. This study provided information on the importance of astemizole-methylene blue combination therapy against malaria and emphasized on the relevance of drug repurposing in malaria. This study shows that the drugs work better as monotherapies and that combinations in these ratios have insignificant antiplasmodial activity.
This is the use of known drugs to treat diseases for which they were not primarily intended [15]. Although not primarily used to treat malaria, both methylene blue and astemizole have been reported to be potent against malaria [14,11]. Hence, there is a potential for both to be repurposed and used in malaria therapy. In this article, we explored the possibility and potential of astemizole-methylene blue combination in vitro against two laboratory maintained *P. falciparum* strains.

2. MATERIALS AND METHODS

2.1 Study Area

The study was conducted at the Department of Tropical and Infectious Diseases (TID), Institute of Primate Research (IPR) in Karen, Nairobi County, Kenya.

2.2 Preparation of Drugs and Chemicals

Anhydrous methylene blue (sourced from Sigma-Aldrich, Germany), was weighed and dissolved in distilled water to produce a 1 mg/ml stock solution [14]. Astemizole (sourced from University of Cape Town – Department of Chemistry) was dissolved in absolute ethanol to produce a 1 mg/ml stock solution. The solutions were filter sterilized through a 0.22 μm membrane filter (Sartorius Stedim Biotech, USA, Ministart ®) and stored at 4°C until use [8]. Astemizole-methylene blue combinations in ratios of 1:1, 1:3, 3:1 were prepared.

2.3 In vitro Assay of *Plasmodium falciparum*

Chloroquine sensitive (3D7) and chloroquine resistant (W2) *Plasmodium falciparum* strains (acquired from Institute of Primate Research and Kenya Medical Research Institute biorepository), respectively, were used. In this study, Sodium chloride (NaCl) gradient methodology was used to culture the parasites as described by Nzila [16]. Each strain was assessed in vitro in triplicate using five concentrations ranging from 7.81 μg/ml to 125 μg/ml of drugs: methylene blue, astemizole and astemizole-methylene blue combination ratios of 1:1, 1:3, and 3:1 as described by Fivelman [17]. *Plasmodium falciparum* parasites (3D7 and W2 strains) were inoculated at 1% parasitemia (>70% ring forms) and 1.5% hematocrit.

2.4 Dosing of Culture Plates with Test Drugs and Incubation of Treated Parasites

Drug assays of astemizole-methylene blue combinations (1:1, 1:3, 3:1) were set up in 96 well plates for each parasite strain. Diluted pellets of *Plasmodium falciparum* parasites were incubated with the drugs for 48 hours at 36.8°C. Thin blood smears were prepared and observed under the microscope (Zeiss standard 20, Germany) with x100 objective under oil immersion. Parasitemia was determined by counting the infected red blood cells relative to the total red blood cells computed:

Parasite load per μl = Number of infected red blood cells/ Number of total red blood cells x 5 x 10^6 (1)

Parasite suppression (%) = Parasitemia in negative control – parasitemia in drug treated groups/ Parasitemia in negative control x 100 (2)

2.5 Statistical Analysis

Data entry and presentation of drug interactions in the form of graphs and tables was done using Microsoft Excel and Microsoft word software 2013 version. Data were imported into Graph Pad Prism software version 7 (California corporation) for variance analysis and differences were considered significant if the P values were less than 0.05 (p< 0.05). Parasite load-drug concentration graphs were plotted in Graph Pad Prism software version 7. From these graphs, Inhibitory Concentration (IC50) of the drugs was determined. Fractional Inhibitory Concentration (FIC) values were calculated from Inhibitory Concentration values using the FIC index formula.

3. RESULTS AND DISCUSSION

3.1 Antiplasmodial Activity of Drug Combinations

In this study, antiplasmodial activity was observed in both mono and combination therapies. Astemizole (AST) and methylene blue (MB) monotherapies showed potency against both *Plasmodium* parasite strains and concurred with findings by Nzila [16] and Chong [11] (Fig. 1a). The parasite loads in methylene blue alone and astemizole alone were less than the load in
the negative control against *Plasmodium falciparum* chloroquine sensitive (3D7). According to the results, the monotherapies were more efficacious at low concentrations. Astemizole- methylene blue 1:1 performed better at both high and low concentrations (Fig. 1b). Astemizole-methylene blue 1:3 and 3:1 had better efficacy as compared to the monotherapies at both low and high concentrations (Fig. 1c and d respectively).

Astemizole-methylene blue 3:1 was the most efficacious test drug against *P. falciparum* chloroquine sensitive (3D7) (*p*=0.0017). These results revealed that for the combination to cause a high reduction in parasitemia, the amount of methylene blue must be less than that of astemizole against *Plasmodium falciparum* chloroquine sensitive (3D7). Astemizole has been shown to be effective against *Plasmodium* chloroquine sensitive strains [18]. A higher concentration of astemizole in the drug combination increased the maximal therapeutic activity against *P. falciparum* chloroquine sensitive (3D7) [19]. At low concentrations, both monotherapies and drug combinations showed antiplasmodial activity (Fig. 2). Astemizole-methylene blue 1:1 performed better at higher concentrations (Fig. 2b). Astemizole-methylene 1:3 and 3:1 were more efficacious at all concentrations and observed to be similar to those in the monotherapies (Fig. 2c and d). The results showed that AST-MB 1:3 had more antiplasmodial activity against *P. falciparum* chloroquine resistant (W2) strain. According to Meissner [13], methylene blue reverses chloroquine sensitivity in *P. falciparum*. More methylene blue in comparison to astemizole therefore increased the susceptibility of the parasite to the drug combination.

**Fig. 1.** Parasitemia of drugs and the control against *Plasmodium falciparum* 3D7 (a) astemizole alone and methylene blue alone, (b) astemizole-methylene blue drug combination (1:1), (c) astemizole-methylene blue drug combination (1:3), (d) astemizole-methylene blue drug combination (3:1)
Fig. 2. Parasitemia of drugs and the control against *Plasmodium falciparum* W2
(a) astemizole alone and methylene blue alone, (b) astemizole-methylene blue drug combination (1:1),
(c) astemizole-methylene blue drug combination (1:3), (d) astemizole-methylene blue drug combination (3:1)

The drugs that caused the greatest reduction in parasitemia against chloroquine sensitive (3D7) and chloroquine resistant (W2) *Plasmodium falciparum* strains are shown in Table 1 and Table 2. However, only AST-MB 3:1 at 31.25 µg/ml caused significant parasite suppression (51%) (p= 0.0017) against chloroquine sensitive (3D7) and AST-MB 1:3 at 31.25 µg/ml caused significant parasite suppression (53%) (p=0.0035) against chloroquine resistant (W2) *Plasmodium* strains. An antimalarial drug with a parasite suppression of 30% is considered ideal [20]. In previous studies, astemizole alone and methylene blue alone each caused 80% parasite suppression against malaria parasites [21,22]. The parasite suppression of the most potent astemizole-methylene blue combinations despite causing parasite suppression that is above the ideal percentage, was less than that of the individual drugs.

### 3.2 Interactions of Drug Combinations

In this study, inhibitory concentration 50 (IC₅₀) showed the efficacy of a drug and potency of antagonists in drug combinations [23]. In Table 3, methylene blue alone had the least IC₅₀ value (17.96±0.22 µg/ml), seconded by AST-MB 3:1 (22.28 ±0.24 µg/ml) against *Plasmodium falciparum* chloroquine sensitive (3D7). Also, methylene blue alone had the least IC₅₀ value (7.69±0.43 µg/ml), seconded by AST-MB 1:3 (15.07±0.60 µg/ml) against *Plasmodium falciparum* chloroquine resistant (W2). These results showed that astemizole alone had less potency as compared to methylene blue alone against both *Plasmodium falciparum* chloroquine sensitive (3D7) and *Plasmodium falciparum* chloroquine resistant (W2) strains.

This According to Te Dorshorst [24], the cut offs for drug interactions (x) are: if x <1 synergistic, 1 ≤ x <2 additive, 2 ≤ x<4 slightly antagonistic, 4 ≥ x antagonistic. The fractional inhibitory concentrations (FIC) of AST-MB combinations (1:1, 1:3, 3:1) against both *Plasmodium falciparum* chloroquine sensitive (3D7) and chloroquine resistant (W2) strains were all greater than 2 and therefore demonstrated
antagonistic interactions [25] (Table 4). Astemizole- methylene blue 1:1 demonstrated more antagonism than both astemizole-methylene blue 3:1 and astemizole-methylene blue 1:3. Drug interactions are highly dependent on the concentration of the drugs in a combination. Therefore, a drug can synergize another drug at one concentration (increase efficacy) or antagonize another drug at a different concentration [26]. Isobolograms further illustrated drug interactions (Figs. 3 and 4). All the drug FIC values were above the cut off line of methylene blue alone and astemizole alone, thus illustrating antagonistic interactions.

Table 1. Drug efficacy against *Plasmodium falciparum* chloroquine sensitive (3D7)

<table>
<thead>
<tr>
<th>Concentration (µg/ml)</th>
<th>Most efficacious drug</th>
<th>Statistical significance (ANOVA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>MB alone</td>
<td>Insignificant</td>
</tr>
<tr>
<td>62.5</td>
<td>AST-MB 1:1</td>
<td>Insignificant</td>
</tr>
<tr>
<td>31.25</td>
<td>AST-MB 3:1</td>
<td>*Significant (d=2, p=0.0017)</td>
</tr>
<tr>
<td>15.63</td>
<td>AST-MB 3:1</td>
<td>Insignificant</td>
</tr>
<tr>
<td>7.81</td>
<td>AST-MB 3:1</td>
<td>Insignificant</td>
</tr>
</tbody>
</table>

*Caused 51% parasite suppression*

Table 2. Drug efficacy against *Plasmodium falciparum* chloroquine resistant (W2)

<table>
<thead>
<tr>
<th>Concentration (µg/ml)</th>
<th>Most efficacious drug</th>
<th>Statistical significance (ANOVA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>AST-MB 3:1 and 1:3</td>
<td>Insignificant</td>
</tr>
<tr>
<td>62.5</td>
<td>AST-MB 3:1</td>
<td>Insignificant</td>
</tr>
<tr>
<td>31.25</td>
<td>AST-MB 1:3</td>
<td>*Significant (d=2, p=0.0035)</td>
</tr>
<tr>
<td>15.63</td>
<td>AST</td>
<td>Insignificant</td>
</tr>
<tr>
<td>7.81</td>
<td>AST-MB 1:1</td>
<td>Insignificant</td>
</tr>
</tbody>
</table>

*Caused 53% parasite suppression*

Table 3. Drug IC50 values

<table>
<thead>
<tr>
<th>Drug</th>
<th>Inhibitory concentration 50 (IC50) (µg/ml)</th>
<th>Ratio</th>
<th>P. falciparum 3D7</th>
<th>P. falciparum W2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylene blue alone</td>
<td>-</td>
<td>17.96±0.22</td>
<td>7.69±0.43</td>
<td></td>
</tr>
<tr>
<td>Astemizole alone</td>
<td>-</td>
<td>23.12±0.30</td>
<td>23.55±0.26</td>
<td></td>
</tr>
<tr>
<td>Astemizole-methylene blue</td>
<td>1:1</td>
<td>23.25±0.66</td>
<td>29.23±0.84</td>
<td></td>
</tr>
<tr>
<td>Astemizole-methylene blue</td>
<td>1:3</td>
<td>34.16±0.37</td>
<td>15.07±0.60</td>
<td></td>
</tr>
<tr>
<td>Astemizole-methylene blue</td>
<td>3:1</td>
<td>22.28±0.24</td>
<td>26.14±0.46</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 3. Isobologram of the drugs against *Plasmodium falciparum* 3D7
Table 4. Fractional Inhibitory Concentrations (FIC) of the drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Ratio</th>
<th>P. falciparum 3D7 FIC value</th>
<th>Interaction</th>
<th>P. falciparum W2 FIC value</th>
<th>Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astemizole-methylene blue</td>
<td>1:1</td>
<td>2.3</td>
<td>antagonistic</td>
<td>5.0</td>
<td>antagonistic</td>
</tr>
<tr>
<td>Astemizole-methylene blue</td>
<td>1:3</td>
<td>3.4</td>
<td>antagonistic</td>
<td>2.6</td>
<td>antagonistic</td>
</tr>
<tr>
<td>Astemizole-methylene blue</td>
<td>3:1</td>
<td>2.2</td>
<td>antagonistic</td>
<td>4.5</td>
<td>antagonistic</td>
</tr>
</tbody>
</table>

4. CONCLUSION

All the test drugs (astemizole alone, methylene blue alone, astemizole-methylene blue (1:1, 1:3 and 3:1) showed antiplasmodial activity against both Plasmodium falciparum chloroquine sensitive (3D7) and chloroquine resistant (W2) strains in vitro. Furthermore, astemizole alone-methylene blue 3:1 caused the highest reduction in parasite load against Plasmodium falciparum chloroquine sensitive (3D7) strain at 31.25 µg/ml (51% parasite suppression), whereas astemizole alone-methylene blue 1:3 drug combination caused the highest reduction in parasite load against Plasmodium falciparum chloroquine resistant (W2) strain at 31.25 µg/ml (53% parasite suppression). Despite the drug combinations offering parasite load reductions that are ideal (> 30%), the values were below those of astemizole alone and methylene blue alone (80%).

This study also showed that astemizole and methylene blue drug combinations interacted antagonistically. As such, astemizole-methylene blue drug combinations in the ratios: 1:1, 1:3 and 3:1, would not be effective when treating malaria caused by Plasmodium falciparum. However, the parasite load suppression of the drug combinations was above 30% but less than the individual drug parasite load suppression of 80%. This therefore showed that astemizole-methylene blue combination in the ratios used, reduces the potency of the drugs. Thus, this study recommends repurposing astemizole and methylene blue drug combinations in other ratios.

ETHICAL APPROVAL

Ethical clearance was sought from the Institutional Scientific Ethical Review Committee (ISERC) at Institute of Primate Research (ISERC/09/2017), which reviews all research protocols carried out in the institute. This committee is mandated by the National government through the National Commission of Science and Technology (NACOSTI).

ACKNOWLEDGEMENTS

The authors would like to thank Kenyatta University, Institute of Primate Research (Department of Tropical and infectious diseases), Kenya Medical Research for their support,
Professor Chibale and Dr Malkeet Kumar from the Department of Chemistry, University of Cape Town for the support in conducting this research. There was no formal funding for this project

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

Nyirongo et al.; SAJP, 4(3): 9-17, 2020; Article no.SAJP.60063

DOI: 10.1128/AAC.48.11.4097-4102.2004


© 2020 Nyirongo et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/60063